Abstract:Abstract Programmed cell death protein 1 (PD-1) is an immune checkpoint (IC) receptor that negatively regulates T cell function. Blocking the interaction of PD-1 with its ligands PD-L1 or PD-L2 unleashes the immune system and enhances anti-tumor responses. Immunotherapy using PD-1 or PD-L1 blocking antibodies has led to a paradigm shift in cancer drug discovery, due to its durable effect against a wide variety of cancers. However, despite its tremendous clinical success in cancer treatment, a significant fraction of patients and tumor types remain unresponsive to this therapy. This has led to the development of combination therapies linking PD-1 checkpoint inhibitors with inhibitors of several other IC receptors. A major challenge in immunotherapy drug development is the lack of quantitative and reproducible functional assays. Existing methods rely heavily on primary immune cells are highly variable and labor-intensive. Here, we report the development of a suite of cell line-based reporter bioassays for monoclonal antibodies targeting human PD-1/PD-L1, or bispecific antibodies targeting PD-1/PD-L1 and a co-stimulatory receptor (e.g., 4-1BB, OX40, ICOS) or an immune inhibitory receptor (e.g., CTLA-4, LAG-3, TIGIT). A mouse PD-1/PD-L1 assay and a human PD-1/PD-L2 assay are also developed and can be used in parallel with human PD-1/PD-L1 assay to enable preclinical studies and assess assay specificity. Each of these assays consist of two engineered cell lines: a T effector cell line that express a luciferase reporter driven by specific promoter/response elements responding to the intracellular signals mediated by the T cell receptor (TCR), with modulation from PD-1 and the second immune receptor, and an engineered artificial antigen presenting cell (aAPC). Importantly, these combination bioassays demonstrate the synergetic effect of PD-1 blockade with blockade of a second IC inhibitor receptor or activation of a costimulatory receptor, thus reflecting the mechanisms of action for the therapeutic antibodies of interest. The bioassays are sensitive and quantitative, are prequalified according to ICH guidelines, and demonstrate the performance characteristics (specificity, precision, accuracy, and linearity) to be used as potency assays for product release and stability studies during immunotherapy drug development. Citation Format: Jun Wang, Julia Gilden, Denise Garvin, Pete Stecha, Jim Hartnett, Frank Fan, Mei Cong, Jamison Grailer. Novel cell-based bioassays for mono- and multi-specific antibodies targeting PD-1/PD-L1 for combination immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3274.

Preparation and application of anti-human PD-L1 monoclonal antibodies

Preparation and characterization of a novel monoclonal antibody against human PD-1

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

[Preparation and Characterization of Three Novel Monoclonal Antibodies Against Human PD-L1].

[Preparation of Two Mouse Anti-Human PD-1 Monoclonal Antibodies and Identification of Their Biological Characteristics].

Preparation and Characterization of a Novel Monoclonal Antibody Against Human PD-L2 (B7-DC)

Using Protein Microarray Technology To Screen Anti-Pd-1 Monoclonal Antibodies For Specificity And Applications In Anatomic Pathology

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development

Development of monoclonal antibodies against PD-L1 and preliminary investigation on potential application in treatment of chronic hepatitis B virus in-fection

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies

Anti-tumor Immunotherapy by Blockade of the PD-1/PD-L1 Pathway with Recombinant Human PD-1-IgV.

Abstract 3274: Novel cell-based bioassays for mono- and multi-specific antibodies targeting PD-1/PD-L1 for combination immunotherapy

A Fully Human Monoclonal Antibody Targeting PD-L1 with Potent Anti-Tumor Activity.

Abstract 3393: Using Protein Microarray Technology to Screen Anti-Pd-1 Monoclonal Antibodies for Specificity and Applications in Anatomic Pathology

CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy

The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

The Preparation of Human Anti-P-Selectin Monoclonal Antibodies